ADVERSE REACTIONS
The most common adverse reaction in double-blind clinical
trials (>5%) in children and adolescents was upper abdominal
pain. The most common adverse reactions in double-blind
clinical trials (>5%) in adult patients were decreased
appetite, headache, dry mouth, nausea, insomnia, anxiety,
dizziness, weight decrease, irritability, and hyperhidrosis.
INDICATION
Methylphenidate hydrochloride extended-release tablets USP is
a CNS stimulant indicated for the treatment of Attention
Deficit Hyperactivity Disorder (ADHD) in children 6 years of
age and older, adolescents, and adults up to the age of 65.
You may report side effects to Trigen Laboratories, LLC at
1-800-444-5164, or to the FDA
at 1-800-FDA-1088.
Please
click here
for Methylphenidate ER full Prescribing Information, including
Boxed Warning.